Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign

Cancer

Volumn 116, Issue 2, 2010, Pages 451-458

  Benz, Matthias R ^a   Czernin, Johannes ^a   Dry, Sarah M ^a   Tap, William D ^a   Allen Auerbach, Martin S ^a   Elashoff, David ^a   Phelps, Michael E ^a   Weber, Wolfgang A ^a   Eilber, Fritz C ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Computed tomography; Malignant peripheral nerve sheath tumor; Neurofibroma; Positron emission tomography; Schwannoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOHEXOL;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; PERIPHERAL NERVE SHEATH TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; NEURILEMMOMA; NEUROFIBROMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 75649094902     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24755     Document Type: Article

References (33)

1. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340-349.
2. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006-2021.
3. McGaughran JM, Harris DI, Donnai D, et al. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 1999;36:197-203.
4. Vauthey JN, Woodruff JM, Brennan MF. Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): a 10-year experience. Ann Surg Oncol. 1995;2: 126-131.
5. Weiss S, Goldblum J. Enzinger and Weiss's Soft Tissue Tumors. St. Louis, MO: Mosby; 2001.
6. Eilber FC, Brennan MF, Eilber FR, Dry SM, Singer S, Kattan MW. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer. 2004;101:2270-2275.
7. Eilber FC, Tap WD, Nelson SD, Eckardt JJ, Eilber FR. Advances in chemotherapy for patients with extremity soft tissue sarcoma. Orthop Clin North Am. 2006;37:15-22.
8. Wiestler O, Radner H. Pathology of neurofibromatosis 1 and 2. In: Huson SM, Hughes RAC, eds. The Neurofibromatosis: A Pathologic and Clinical Overview. Cambridge, UK: Chapman and Hall; 1994:135-160.
9. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62:1573-1577.
10. Rha SE, Byun JY, Jung SE, Chun HJ, Lee HG, Lee JM. Neurogenic tumors in the abdomen: tumor types and imaging characteristics. Radiographics. 2003;23:29-43.
11. Beggs AD, Hain SF, Curran KM, O'Doherty MJ. FDGPET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging. 2002; 29:542-546.
12. Hain SF, Curran KM, Beggs AD, Fogelman I, O'Doherty MJ, Maisey MN. FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med. 2001;28:1336-1340.
13. Beyer T, Antoch G, Muller S, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45(suppl 1):25S-35S.
14. Halpern BS, Dahlbom M, Auerbach MA, et al. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med. 2005; 46:603-607.
15. Halpern BS, Dahlbom M, Quon A, et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med. 2004;45:797-801.
16. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998;25:2046-2053.
17. Benz MR, Evilevitch V, Allen-Auerbach MS, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008; 49:1038-1046.
18. Weiss SW, Langloss JM, Enzinger FM. Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest. 1983;49:299-308.
19. Bredella MA, Torriani M, Hornicek F, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2007;189:928-935.
20. Ferner RE, Golding JF, Smith M, et al. [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19:390-394.
21. Ferner RE, Lucas JD, O'Doherty MJ, et al. Evaluation of fluorodeoxyglucose positron emission tomography (FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000; 68:353-357.
22. Cardona S, Schwarzbach M, Hinz U, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDGPET) to assess the nature of neurogenic tumours. Eur J Surg Oncol. 2003;29:536-541.
23. Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009;36:751-757.
24. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for highgrade extremity soft tissue sarcomas. J Clin Oncol. 2001;19: 3203-3209.
25. Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15:1667-1672.
26. Shintani K, Matsumine A, Kusuzaki K, et al. Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch. 2006;449: 673-681.
27. Ahmed AR, Watanabe H, Aoki J, Shinozaki T, Takagishi K. Schwannoma of the extremities: the role of PET in preoperative planning. Eur J Nucl Med. 2001;28:1541-1551.
28. Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary JF. Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. AJR Am J Roentgenol. 2004;182:971-974.
29. Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med. 2000;27:1509-1517.
30. Salla JT, Johann AC, Lana AM, do Carmo MA, Nunes FD, Mesquita RA. Immunohistochemical study of GLUT-1 in oral peripheral nerve sheath tumors. Oral Dis. 2008;14:510-513.
31. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122-127.
32. Benz MR, Czernin J, Allen-Auerbach MS, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15:2856-2863.
33. Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008;14:715-720.